H λιξισενατίδη είναι αντιδιαβητικό φάρμακο [αγωνιστής υποδοχέα γλυκαγονοειδούς πεπτιδίου-1, glucagon-likepeptide 1 (GLP-1) receptoragonist] . Περισσόπτερα βλέπε: Lyxumia
Βιβλιογραφική Τεκμηρίωση:
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies. Shaefer CF Jr. Clin Diabetes. 2016 Apr;34(2):81-5. doi: 10.2337/diaclin.34.2.81.
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. Derosa G, Maffioli P. N Engl J Med. 2016 Mar 17;374(11):1095. doi: 10.1056/NEJMc1600140#SA2.
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of lixisenatide and other glucagon-like peptide-1 receptor agonists. Giorgino F, Bonadonna RC, Gentile S, Vettor R, Pozzilli P. Diabetes Metab Res Rev. 2016 Jan 20. doi: 10.1002/dmrr.2775.
